<DOC>
	<DOCNO>NCT02404259</DOCNO>
	<brief_summary>This study ass pharmacokinetics TDF Thai HIV-infected child</brief_summary>
	<brief_title>PK TDF Thai HIV-infected Children</brief_title>
	<detailed_description>HIV-infected child currently TDF-base daily regimen enrol study . PK visit perform least 1 month change regimen daily regimen . Adherence 3 day PK study confirm use adherence questionnaire . 100 % adherence need PK study . If adherence problem PK visit , PK study defer least 3 day . On PK visit , blood drawn perform 0 , 2 , 4 , 6 , 8 , 10 , 12 , 24 hr . take ARVs PK study . Blood drawn safety evaluation draw time-point PK visit . There study drug study . All ARVs patient take accord patient 's requirement , physician judgment . ARVs dosage follow Thai national pediatric guideline . CBC , CD4 , viral RNA , viral resistance , ALT , cholesterol , triglyceride result visit within 4 week window period . Statistical consideration Sample size calculation . There pharmacokinetic data child . In adult , mean ( SD ) AUC follow administration 300mg Viread tablet fast state 2.29 ( 0.69 ) microg.hr/mL . In patient take lopinavir/ritonavir atazanavir/ritonavir , mean AUC TDF increase 32 % 24 % respectively . Efavirenz change AUC TDF . If weight adjust dose TDF child adolescents achieves AUC adult concomitant dose protease inhibitor increase TDF AUC 30 % concomitant dosing Efavirenz change TDF AUC , 20 treat Efavirenz 20 patient treat PI base regimen would provide 90 % power detect difference 5 % significance level . Statistical Analysis . Primary endpoint Pharmacokinetic parameter calculate base individual plasma concentration v time data , use noncompartmental method . Data summarize overall whether patient take PI EFV-based regimen . Formal statistical comparison parameter make use ANOVA technique non-parametric equivalent appropriate . Effect size 95 % confidence interval give comparison .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>child age 818 year document HIV infection currently TDF daily regimen sign informed consent child care taker refuse participate study severity adverse event grade 3 thirty day participate study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>TDF</keyword>
	<keyword>HIV-infected child</keyword>
	<keyword>Thai</keyword>
	<keyword>non-nucleoside reverse transcriptase inhibitor ( NNRTI )</keyword>
	<keyword>ritonavir-boosted protease inhibitor ( bPI )</keyword>
	<keyword>less eighteen year old</keyword>
</DOC>